Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR3 | P51677 | 19/20 | 0.62 |
| ▸ | HTR2A | P28223 | 1/20 | 0.61 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6215889 | 1.00 | CCR3 (0.62) | CCR3HTR2ACYP2D6 | |
| SCHEMBL6214548 | 1.00 | CCR3 (0.62) | CCR3HTR2ACYP2D6 | |
| SCHEMBL6214531 | 1.00 | CCR3 (0.62) | CCR3HTR2ACYP2D6 | |
| SCHEMBL6216640 | 0.91 | CCR3 (0.64) | CCR3HTR2ACYP2D6 | |
| SCHEMBL6216259 | 0.91 | CCR3 (0.64) | CCR3HTR2ACYP2D6 | |
| SCHEMBL6216261 | 0.91 | CCR3 (0.64) | CCR3HTR2ACYP2D6 | |
| SCHEMBL6213690 | 0.90 | CCR3 (0.69) | CCR3HTR2A | |
| SCHEMBL6213693 | 0.90 | CCR3 (0.69) | CCR3HTR2A | |
| SCHEMBL6216253 | 0.90 | CCR3 (0.69) | CCR3HTR2A | |
| SCHEMBL6216668 | 0.89 | CCR3 (0.62) | CCR3HTR2ACYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040002515-A1 | N-ureidoalkyl-piperidines as modulators of chemokine receptor activity | KO SOO S (US) | 2004-01-01 | — | — | US | claimed |
| US-6486180-B1 | N-ureidoalkyl-piperidines as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-11-26 | — | — | US | claimed |
| US-20050192291-A1 | N-ureidoalkyl-piperidines as modulators of chemokine receptor activity | KO SOO S (US) | 2005-09-01 | — | — | US | disclosed |
| EP-1158980-B1 | N-UREIDOALKYL-PIPERIDINES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | BRISTOL MYERS SQUIBB PHARMA CO (US) | 2005-08-24 | — | — | EP | disclosed |
| US-6875776-B2 | N-ureidoalkyl-piperidines as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2005-04-05 | — | — | US | disclosed |
| US-20040002515-A1 | N-ureidoalkyl-piperidines as modulators of chemokine receptor activity | KO SOO S (US) | 2004-01-01 | — | — | US | disclosed |
| US-6486180-B1 | N-ureidoalkyl-piperidines as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-11-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040002515-A1 | N-ureidoalkyl-piperidines as modulators of chemokine receptor activity | CCR3, CCR1, CCR10 | CCR3 1/4885HTR2A 1608/4885CYP2D6 3262/4885 |
| US-20050192291-A1 | N-ureidoalkyl-piperidines as modulators of chemokine receptor activity | CCR3, CCR1, ACKR3 | CCR3 1/4885HTR2A 1476/4885CYP2D6 3450/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.